/ Print /

Drug costs

Five questions for CVS Health’s Troyen A. Brennan, MD, MPHCVS Health’s Troyen A. Brennan, MD, MPH, brings attention to a unique specialty pharmacy model and value-based contracting.
CMS plan to slash 340B payments under fire by hospitalsHere are four ways CMS’ final rule related to the 340B Drug Pricing Program could affect the healthcare industry.
Controversy heats up over pharmacy benefit manager DIR feesPBMs make the argument for DIR fees after a litany of complaints from industry stakeholders.
When given the chance, will patients choose cheaper prescription drugs?A new UC Berkeley study has surprising findings about reference pricing and patient drug selection.
How to approach value in oncologyAn eye-opening study by Precision for Value assesses cancer value frameworks.
Top 3 factors in biosimilar coverageAn Avalere study has interesting findings about payer acceptance of biosimilars.
ICER, VA join to work on drug value, price negotiationsAnalysts discuss how pharmacoeconomics will make a difference in treatment decisions.
Opinion: Top 2 takeaways from UBS Global Healthcare ConferenceThe conference raised important points about unregulated growth opportunities and new pharmacy arena players.
What's missing in hep C drugsPayers have unmet needs in the changing hepatitis C (HCV) space, according to a recent survey. The survey, from Precision for Value, highlights what can be done to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.
Five things to know about Trump’s FDA lead pick GottliebOn March 10, the White House announced that President Donald Trump selected Scott Gottlieb, MD, who has worked for FDA in the past, as his choice to head the FDA. Here are five things managed healthcare executives should know about the pick.